search
Back to results

The Effect of Omega-3 FA on Hypertriglyceridemia in Patients With T2DM(OCEAN)

Primary Purpose

Type 2 Diabetes Mellitus, Hypertriglyceridemia

Status
Unknown status
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
Omega-3 fatty acid
Placebos
Sponsored by
Shanghai Jiao Tong University School of Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus

Eligibility Criteria

20 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Diagnosed type 2 diabetes defined as WHO (1999) diagnostic criteria ; Both Genders Eligible;
  2. Men or women aged 20 to 75 years;
  3. Stable dosage of oral anti-diabetic medicine ,stable glycemia control(HbA1c<7.5%), unchanged antidiabetic therapy during the trial;
  4. Hypertriglycerides (3.4mmol/L≤mean fasting blood triglycerides<22.60mmol/L, and not receiving any lipid lowering therapy for 3 days continuously or accumulated 7 days within 6 weeks before screening).

Exclusion Criteria:

  1. Uncontrolled blood pressure (defined as systolic blood pressure>180mmHg or diastolic blood pressure>100mmHg);
  2. Other diseases affecting lipid and glucose metabolism: hyperthyroidism,cushing syndrome ect;
  3. Receiving insulin treatment in 6 months before recruitment;
  4. Diagnosed heart failure, defined as New York Heart Association class III or IV;
  5. Histories of acute or chronic pancreatitis,or cholelithiasis (except those received cholecystectomy)
  6. Significant impaired liver function (defined as alanine transaminase (ALT)> 3 times upper limit of normal), or active liver disease;
  7. PLT<60×109/L,Hb<100g/L;
  8. Impaired renal function (defined as serum creatinine> 135 mmol/L(1.5 mg/dL, male) and > 110 mmol/L (1.3 mg/dL,female);
  9. Recorded history of malignant tumor in the past 2 years;
  10. Histories of acute cerebrovascular accident within 6 months;
  11. Pregnancy;
  12. Known history of allergy to fish, shellfish and omega-3 fatty acids, or ineffective treatment of omega-3 fatty acids;
  13. Simultaneous participation in any other clinical trial of an active pharmacologic agent within 30 days;
  14. Other situations that interfere with the subject's ability to comply with study instructions;
  15. Any other condition that investigators believe would interfere with the subject's ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results or put the subject at undue risk.

Sites / Locations

  • Ruijin hospital, Shanghai Jiao-Tong University School of MedicineRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Group A Drug

Group B Drug

Arm Description

Omega-3 fatty acids capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks Other Names: Omega-3 Fatty Acid fish oil Omega 3 Treasure

Matching placebo capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks

Outcomes

Primary Outcome Measures

Change in serum triglycerides from baseline
With aid of autoanalyser, the investigators will measure the serum triglycerides in blood samples before and after treatment.
Change in blood metabolomics profile of lipid species from baseline
With aid of LC/MS and GC/MS, the investigators will measure blood metabolomics profile of lipid species before and after treatment. The metabolomics measurement will help to detect the profile of all kinds of lipids species. The composition change of all these biological molecular induced by the treatment is our major interest rather than single molecular quantification.

Secondary Outcome Measures

Change in serum metabolomics profile of bile acids from baseline
With aid of LC/MS and GC/MS technique, the investigators will measure the blood metabolomics molecular profile of bile acids in blood samples before and after treatment.
Change in serum metabolomics profile of amino acid species from baseline
With aid of LC/MS and GC/MS technique, the investigators will measure the blood metabolomics molecular profile of amino acid species before and after treatment.
Change in serum Gut microbiome from baseline
With aid of quantitative real-time PCR technique, the investigators will measure gut microbiome in fecal samples before and after treatment.
Change in fasting glucose levels from baseline
With aid of autoanalyser, the investigators will measure fasting glucose levels before and after treatment.
Change in 2-hour postprandial glucose levels from baseline
With aid of autoanalyser, the investigators will measure the 2-hour postprandial glucose levels before and after treatment.
Change in HbA1c from baseline
With aid of HPLC technique, the investigators will measure the HbA1c levels before and after treatment.
Change in Non-HDL-C from baseline
With aid of autoanalyser, the investigators will measure the non-HDL-c levels before and after treatment.
Change in serum total Cholesterol from baseline
With aid of autoanalyser, the investigators will measure serum total cholesterol levels before and after treatment.
Change in serum VLDL-c from baseline
With aid of autoanalyser, the investigators will measure serum VLDL-c levels before and after treatment.
Change in serum HDL-c from baseline
With aid of autoanalyser, the investigators will measure serum HDL-c levels before and after treatment.
Change in serum LDL-c from baseline
With aid of autoanalyser, the investigators will measure serum LDL-c levels before and after treatment.
Change in LDL-C/HDL-C from baseline
The LDL-C/HDL-C will be calculated by the ratio of the LDL-C divided by HDL-C before and after treatment.
Change in serum Apo B from baseline
With aid of autoanalyser, the investigators will measure serum Apo B levels before and after treatment.
Change in serum AST from baseline
With aid of autoanalyser, the investigators will measure serum AST levels before and after treatment.
Change in serum ALT from baseline
In aid of autoanalyser, the investigators will measure serum ALT levels before and after treatment.
Change in serum inflammation markers from baseline
With aid of autoanalyser, the investigators will measure hs-CRP, TNF-alfa, IL-6, and IL-8 etc before and after treatment.
Change in liver fat content from baseline
With aid of ultrasonic diagnostic apparatus, the investigators will measure the fat content in liver before and after treatment.
Change in Ankle-Brachial Index from baseline
The ABI value will be measured by PWV/ABI-form device (OMRON Colin Medical Instruments) before and after treatment.
Change in Brachial-ankle pulse wave velocity from baseline
The baPWV value will be measured by PWV/ABI form device (OMRON Colin Medical Instruments) before and after treatment.
Change in enrichment of fish oil in red blood cell from baseline
With aid of HPLC-ESI-MS/MS, the investigators will measure the enrichment of fish oil in red blood cell before and after treatment
Pharmacogenomics analysis
With aid of blood DNA genotyping,the investigators will compare the genotype of FASD1,FASD2 ect and the lipid lowering effect of omega-3

Full Information

First Posted
April 15, 2017
Last Updated
April 27, 2017
Sponsor
Shanghai Jiao Tong University School of Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT03120299
Brief Title
The Effect of Omega-3 FA on Hypertriglyceridemia in Patients With T2DM(OCEAN)
Official Title
The Effect of Omega-3 Fatty Acids on Hypertriglyceridemia in Patients With Type 2 Diabetes Mellitus
Study Type
Interventional

2. Study Status

Record Verification Date
April 2017
Overall Recruitment Status
Unknown status
Study Start Date
May 1, 2017 (Anticipated)
Primary Completion Date
June 2018 (Anticipated)
Study Completion Date
December 2018 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Shanghai Jiao Tong University School of Medicine

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The purpose of this study is to conduct a multicenter randomized, double-blind, placebo-controlled clinical trial, evaluating the effects and change of lipid metabolism, especially of triglyceride after omega-3 administration in type 2 diabetes patients with hypertriglyceride.
Detailed Description
In the present study, about 350 type 2 diabetes patients with hypertriglyceride will be enrolled from multiple centers in China. Randomization was computer generated and stratified by center. After screening, eligible subjects will be randomly assigned into one of the following two groups: Omega-3 fatty acids capsules ( 2pills bid) and placebo capsules (2pills bid). Blood, feces and urine samples will be collected before and after treatment. Triglycerides (TG), total cholesterol (TC), LDL-C, HDL-C, HbA1C, fasting plasma glucose (FPG), postprandial plasma glucose (PPG) will be measured. Blood metabolomics profiles of lipids, amino acids, bile acids, the change of gut microbiota, and pharmacogenomic components and parameters will be evaluated too.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus, Hypertriglyceridemia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
350 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Group A Drug
Arm Type
Experimental
Arm Description
Omega-3 fatty acids capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks Other Names: Omega-3 Fatty Acid fish oil Omega 3 Treasure
Arm Title
Group B Drug
Arm Type
Placebo Comparator
Arm Description
Matching placebo capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks
Intervention Type
Drug
Intervention Name(s)
Omega-3 fatty acid
Other Intervention Name(s)
fish oil supplement
Intervention Description
Omega-3 fatty acids capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks
Intervention Type
Drug
Intervention Name(s)
Placebos
Intervention Description
Matching placebo capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks
Primary Outcome Measure Information:
Title
Change in serum triglycerides from baseline
Description
With aid of autoanalyser, the investigators will measure the serum triglycerides in blood samples before and after treatment.
Time Frame
12 weeks
Title
Change in blood metabolomics profile of lipid species from baseline
Description
With aid of LC/MS and GC/MS, the investigators will measure blood metabolomics profile of lipid species before and after treatment. The metabolomics measurement will help to detect the profile of all kinds of lipids species. The composition change of all these biological molecular induced by the treatment is our major interest rather than single molecular quantification.
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Change in serum metabolomics profile of bile acids from baseline
Description
With aid of LC/MS and GC/MS technique, the investigators will measure the blood metabolomics molecular profile of bile acids in blood samples before and after treatment.
Time Frame
12 weeks
Title
Change in serum metabolomics profile of amino acid species from baseline
Description
With aid of LC/MS and GC/MS technique, the investigators will measure the blood metabolomics molecular profile of amino acid species before and after treatment.
Time Frame
12 weeks
Title
Change in serum Gut microbiome from baseline
Description
With aid of quantitative real-time PCR technique, the investigators will measure gut microbiome in fecal samples before and after treatment.
Time Frame
12 weeks
Title
Change in fasting glucose levels from baseline
Description
With aid of autoanalyser, the investigators will measure fasting glucose levels before and after treatment.
Time Frame
12 weeks
Title
Change in 2-hour postprandial glucose levels from baseline
Description
With aid of autoanalyser, the investigators will measure the 2-hour postprandial glucose levels before and after treatment.
Time Frame
12 weeks
Title
Change in HbA1c from baseline
Description
With aid of HPLC technique, the investigators will measure the HbA1c levels before and after treatment.
Time Frame
12 weeks
Title
Change in Non-HDL-C from baseline
Description
With aid of autoanalyser, the investigators will measure the non-HDL-c levels before and after treatment.
Time Frame
12 weeks
Title
Change in serum total Cholesterol from baseline
Description
With aid of autoanalyser, the investigators will measure serum total cholesterol levels before and after treatment.
Time Frame
12 weeks
Title
Change in serum VLDL-c from baseline
Description
With aid of autoanalyser, the investigators will measure serum VLDL-c levels before and after treatment.
Time Frame
12 weeks
Title
Change in serum HDL-c from baseline
Description
With aid of autoanalyser, the investigators will measure serum HDL-c levels before and after treatment.
Time Frame
12 weeks
Title
Change in serum LDL-c from baseline
Description
With aid of autoanalyser, the investigators will measure serum LDL-c levels before and after treatment.
Time Frame
12 weeks
Title
Change in LDL-C/HDL-C from baseline
Description
The LDL-C/HDL-C will be calculated by the ratio of the LDL-C divided by HDL-C before and after treatment.
Time Frame
12 weeks
Title
Change in serum Apo B from baseline
Description
With aid of autoanalyser, the investigators will measure serum Apo B levels before and after treatment.
Time Frame
12 weeks
Title
Change in serum AST from baseline
Description
With aid of autoanalyser, the investigators will measure serum AST levels before and after treatment.
Time Frame
12 weeks
Title
Change in serum ALT from baseline
Description
In aid of autoanalyser, the investigators will measure serum ALT levels before and after treatment.
Time Frame
12 weeks
Title
Change in serum inflammation markers from baseline
Description
With aid of autoanalyser, the investigators will measure hs-CRP, TNF-alfa, IL-6, and IL-8 etc before and after treatment.
Time Frame
12 weeks
Title
Change in liver fat content from baseline
Description
With aid of ultrasonic diagnostic apparatus, the investigators will measure the fat content in liver before and after treatment.
Time Frame
12 weeks
Title
Change in Ankle-Brachial Index from baseline
Description
The ABI value will be measured by PWV/ABI-form device (OMRON Colin Medical Instruments) before and after treatment.
Time Frame
12 weeks
Title
Change in Brachial-ankle pulse wave velocity from baseline
Description
The baPWV value will be measured by PWV/ABI form device (OMRON Colin Medical Instruments) before and after treatment.
Time Frame
12 weeks
Title
Change in enrichment of fish oil in red blood cell from baseline
Description
With aid of HPLC-ESI-MS/MS, the investigators will measure the enrichment of fish oil in red blood cell before and after treatment
Time Frame
12 weeks
Title
Pharmacogenomics analysis
Description
With aid of blood DNA genotyping,the investigators will compare the genotype of FASD1,FASD2 ect and the lipid lowering effect of omega-3
Time Frame
12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosed type 2 diabetes defined as WHO (1999) diagnostic criteria ; Both Genders Eligible; Men or women aged 20 to 75 years; Stable dosage of oral anti-diabetic medicine ,stable glycemia control(HbA1c<7.5%), unchanged antidiabetic therapy during the trial; Hypertriglycerides (3.4mmol/L≤mean fasting blood triglycerides<22.60mmol/L, and not receiving any lipid lowering therapy for 3 days continuously or accumulated 7 days within 6 weeks before screening). Exclusion Criteria: Uncontrolled blood pressure (defined as systolic blood pressure>180mmHg or diastolic blood pressure>100mmHg); Other diseases affecting lipid and glucose metabolism: hyperthyroidism,cushing syndrome ect; Receiving insulin treatment in 6 months before recruitment; Diagnosed heart failure, defined as New York Heart Association class III or IV; Histories of acute or chronic pancreatitis,or cholelithiasis (except those received cholecystectomy) Significant impaired liver function (defined as alanine transaminase (ALT)> 3 times upper limit of normal), or active liver disease; PLT<60×109/L,Hb<100g/L; Impaired renal function (defined as serum creatinine> 135 mmol/L(1.5 mg/dL, male) and > 110 mmol/L (1.3 mg/dL,female); Recorded history of malignant tumor in the past 2 years; Histories of acute cerebrovascular accident within 6 months; Pregnancy; Known history of allergy to fish, shellfish and omega-3 fatty acids, or ineffective treatment of omega-3 fatty acids; Simultaneous participation in any other clinical trial of an active pharmacologic agent within 30 days; Other situations that interfere with the subject's ability to comply with study instructions; Any other condition that investigators believe would interfere with the subject's ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results or put the subject at undue risk.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Guang Ning, MD, PHD
Phone
+8621-64370045
Ext
671817
Email
guangning@medmail.com.cn
First Name & Middle Initial & Last Name or Official Title & Degree
Jieli Lu, MD, PHD
Phone
+8621-64370045
Ext
671817
Email
jielilu@hotmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Guang Ning, MD, PHD
Organizational Affiliation
Ruijin Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ruijin hospital, Shanghai Jiao-Tong University School of Medicine
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200025
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Guang Ning, Professor
Phone
8621-64370045
Ext
665344
Email
feifei1116@hotmail.com
First Name & Middle Initial & Last Name & Degree
Guang Ning, Professor

12. IPD Sharing Statement

Learn more about this trial

The Effect of Omega-3 FA on Hypertriglyceridemia in Patients With T2DM(OCEAN)

We'll reach out to this number within 24 hrs